Taysha Gene Therapies, Inc.
TSHA
$4.06
-$0.37-8.35%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -13.73% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -13.73% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -13.73% | |||
| SG&A Expenses | -3.71% | 5.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.39% | 21.14% | |||
| Operating Income | -27.18% | -24.89% | |||
| Income Before Tax | -21.77% | -24.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.77% | -24.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.77% | -24.86% | |||
| EBIT | -27.18% | -24.89% | |||
| EBITDA | -27.43% | -25.25% | |||
| EPS Basic | -2.66% | -12.89% | |||
| Normalized Basic EPS | -8.63% | -14.87% | |||
| EPS Diluted | -2.66% | -12.89% | |||
| Normalized Diluted EPS | -8.63% | -14.87% | |||
| Average Basic Shares Outstanding | 18.56% | 10.65% | |||
| Average Diluted Shares Outstanding | 18.56% | 10.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||